Journal of Thoracic Oncology最新文献

{"title":"Screening-Detected versus Interval Lung Cancer in the Biennial Korean National Lung Cancer Screening Program: Proportion, Characteristics, and Mortality.","authors":"Hyungjin Kim, Eunseo Jo, Jinseob Kim, Seung Hun Jang, Joo Sung Sun, Gong Yong Jin, Hyae Young Kim, Yeol Kim, Jin Mo Goo","doi":"10.1016/j.jtho.2025.08.024","DOIUrl":"https://doi.org/10.1016/j.jtho.2025.08.024","url":null,"abstract":"<p><strong>Introduction: </strong>Interval lung cancers (ILCs) are key indicators of lung cancer screening (LCS) performance. However, data on the proportion, characteristics, and mortality of ILCs under biennial screening in Asian populations remain limited.</p><p><strong>Methods: </strong>We analyzed participants from the baseline biennial Korean national LCS program between 2019 and 2020. Screening-detected lung cancers (SLCs) were defined as those diagnosed within 1 year of a positive screening result. ILCs were defined as cancers diagnosed more than 1 year after a negative screening result but within 2 years or before the next screening. Risk factors for ILC were assessed using multivariable logistic regression among participants with a negative screening result. All-cause mortality was compared between SLCs and ILCs using multivariable Cox regression analysis.</p><p><strong>Results: </strong>Among 124,595 participants, SLCs and ILCs occurred in 0.56% and 0.17%, respectively. ILCs accounted for 18.5% of all lung cancers within 2 years; 65.4% were in Lung-RADS category 1. Risk factors for ILC included older age (adjusted odds ratio [OR], 1.14; 95% CI: 1.11-1.17; P<0.001), greater smoking exposure (adjusted OR, 1.010; 95% CI: 1.004-1.016; P=0.002), a history of malignancy (adjusted OR, 2.22; 95% CI: 1.41-3.51; P<0.001), emphysema (adjusted OR, 2.88; 95% CI: 2.15-3.85; P<0.001), and interstitial lung abnormalities (adjusted OR, 4.16; 95% CI: 2.88-6.01; P<0.001). ILCs showed higher all-cause mortality than SLCs (adjusted hazard ratio, 1.43; 95% CI: 1.13-1.80; P=0.002).</p><p><strong>Conclusions: </strong>ILCs are common under biennial LCS, making it potentially suboptimal for Asian heavy smokers.</p>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":" ","pages":""},"PeriodicalIF":20.8,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Translational analysis of NSD3 gene amplification in lung squamous cell carcinoma: Clinical and prognostic insights from histopathological analysis of patient samples.","authors":"Shugo Takahashi, Tetsuro Taki, Nobuyuki Nakamura, Ayako Ura, Shoko Kubota, Tomohiro Miyoshi, Kenta Tane, Yuki Matsumura, Joji Samejima, Keiju Aokage, Masashi Wakabayashi, Yukiko Sasahara, Michiko Nagamine, Motohiro Kojima, Shingo Sakashita, Naoya Sakamoto, Takuo Hayashi, Kazuya Takamochi, Kenji Suzuki, Masahiro Tsuboi, Genichiro Ishii","doi":"10.1016/j.jtho.2025.08.022","DOIUrl":"https://doi.org/10.1016/j.jtho.2025.08.022","url":null,"abstract":"<p><strong>Introduction: </strong>Nuclear receptor-binding SET domain 3 (NSD3) has been implicated as a driver of lung squamous cell carcinoma (LUSC) in preclinical studies. However, its clinicopathological characteristics and prognostic significance remain unclear. To address this, we performed histopathological analysis of patient tissues.</p><p><strong>Methods: </strong>The NSD3 gene copy number was evaluated using fluorescence in situ hybridization in multiple cohorts of surgically resected LUSC cases, categorized into the amplification (Amp) or diploidy (Diploidy) groups. Clinicopathological characteristics were compared, and AI-based histopathological image analysis evaluated the associations between NSD3 amplification, its protein expression, and cancer cell proliferation activity.</p><p><strong>Results: </strong>In the original cohort, NSD3 amplification was detected in 106 (39.6%) patients. NSD3 protein expression was positively correlated with the NSD3 gene copy number (r = .528, P < .001). The Amp group exhibited higher mitotic counts (18 vs. 13, P = .004) and Ki-67 index (18.5% vs. 13.6%, P = .009) than the Diploidy group. The Amp group had shorter overall survival than the Diploidy group (110.6 vs. 125.3 months, P = .030), and multivariable analysis identified NSD3 amplification as an independent poor prognostic factor (HR = 1.59, P = .049). Furthermore, validation cohort analyses demonstrated consistent associations of NSD3 gene amplification with protein expression and cell proliferation, with comparable hazard ratios in prognostic evaluation.</p><p><strong>Conclusions: </strong>Our study highlights the clinical relevance of NSD3 amplification in LUSC through patient tissue analyses. These findings emphasize the potential of NSD3 as a prognostic biomarker and therapeutic target, bridging the gap between preclinical research and clinical application.</p>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":" ","pages":""},"PeriodicalIF":20.8,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145006400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Setting Expectations: Using Real-World Data to Guide Patients on Frontline Osimertinib","authors":"Jennifer W. Carlisle MD,&nbsp;Ticiana Leal MD","doi":"10.1016/j.jtho.2025.07.006","DOIUrl":"10.1016/j.jtho.2025.07.006","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 9","pages":"Pages 1161-1163"},"PeriodicalIF":20.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144989736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Sequences in BRAF-V600–Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) Immunotherapy","authors":"Marcel Wiesweg MD ,&nbsp;Ali Alaffas ,&nbsp;Anna Rasokat MSc ,&nbsp;Felix Carl Saalfeld MD ,&nbsp;Maximilian Rost MD ,&nbsp;Christin Assmann MD ,&nbsp;Franziska Herster PhD ,&nbsp;Moritz Hilbrandt MD ,&nbsp;Frank Griesinger MD ,&nbsp;Anna Kron PhD ,&nbsp;Julia Roeper PhD ,&nbsp;Franziska Glanemann MD ,&nbsp;Cornelia Kropf-Sanchen MD ,&nbsp;Martin Reck MD ,&nbsp;Jonas Kulhavy MSc ,&nbsp;Albrecht Stenzinger MD ,&nbsp;Jürgen Wolf MD ,&nbsp;Martin Sebastian MD ,&nbsp;Martin Schuler MD ,&nbsp;Martin Wermke MD ,&nbsp;Matthias Scheffler MD","doi":"10.1016/j.jtho.2025.04.016","DOIUrl":"10.1016/j.jtho.2025.04.016","url":null,"abstract":"<div><h3>Background</h3><div>Targeted treatment of patients with metastatic <em>BRAF</em>-V600–mutated NSCLC using BRAF/MEK-inhibitors is effective but limited by acquired resistance. Patients with <em>BRAF</em>-mutant NSCLC may derive long-lasting benefit from immune checkpoint inhibition with programmed death-1/programmed death-ligand 1 (PD-L1) antibodies (immuno-oncology [IO]). Although IO is the preferred first-line therapy in <em>BRAF</em>-mutated melanoma, the optimal treatment sequence in <em>BRAF</em>-mutated NSCLC is not defined.</div></div><div><h3>Methods</h3><div>This retrospective study investigated the clinical outcome of patients with metastatic <em>BRAF</em>-V600–mutated NSCLC diagnosed in the German national Network Genomic Medicine Lung Cancer.</div></div><div><h3>Results</h3><div>We identified 205 patients with <em>BRAF</em>-V600–mutated NSCLC; 175 patients received first-line therapy with dabrafenib/trametinib (DAB/TRM, 65.1%), IO alone (19.4%), or chemotherapy-IO (15.4%). Overall survival (OS) and time-to-treatment failure of first-line therapy was identical for patients receiving first-line DAB/TRM (median OS 28.0 months) or chemo/IO (27.8 months, hazard ratio [HR] 1.1, <em>p</em> = 0.68). Female patients had superior OS (HR 0.65, <em>p</em> = 0.049, confirmed in multivariate model), which was mainly driven by superior OS of female to that of male patients receiving first-line DAB/TRM (OS HR 0.53, <em>p</em> = 0.015). There was no sex difference in survival of patients receiving IO-based first-line treatment (OS HR 1.02). Surprisingly, high PD-L1 status (tumor proportion score ≥50%) was associated with shortened time-to-treatment failure in first-line treatment (HR 1.83, <em>p</em> = 0.002, confirmed in multivariate models adjusting for sex; OS with nonsignificant trend, HR 1.4), regardless of whether the first-line regimen was IO-based or targeted therapy.</div></div><div><h3>Conclusions</h3><div>Targeted or IO-based first-line treatment of <em>BRAF</em>-V600–mutated NSCLC has similar survival outcomes. Sex and PD-L1 status may support decision-making at the individual patient level.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 9","pages":"Pages 1328-1335"},"PeriodicalIF":20.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144027278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Phase II Multicenter Trial","authors":"Sehhoon Park MD ,&nbsp;Hee Kyung Ahn MD ,&nbsp;Seoyoung Lee MD ,&nbsp;Young Joo Min MD ,&nbsp;Jinyong Kim MD ,&nbsp;Hyun Ae Jung MD ,&nbsp;Jong-Mu Sun MD ,&nbsp;Se-Hoon Lee MD ,&nbsp;Jin Seok Ahn MD ,&nbsp;Myung-Ju Ahn MD ,&nbsp;Jii Bum Lee MD ,&nbsp;Sun Min Lim MD ,&nbsp;Hye Ryun Kim MD ,&nbsp;Byoung Chul Cho MD ,&nbsp;Min Hee Hong MD","doi":"10.1016/j.jtho.2025.05.006","DOIUrl":"10.1016/j.jtho.2025.05.006","url":null,"abstract":"<div><h3>Introduction</h3><div>Uncommon <em>EGFR</em> mutations comprise 10% to 20% of all <em>EGFR</em> mutations in NSCLC and generally report reduced responsiveness to EGFR tyrosine kinase inhibitors (TKIs). Lazertinib, a third-generation EGFR-TKI, has found efficacy in common <em>EGFR</em> mutations, but its potential in uncommon mutations remains unexplored. This study investigated the efficacy and safety of lazertinib in patients with NSCLC with uncommon <em>EGFR</em> mutations.</div></div><div><h3>Method</h3><div>This single-arm, multicenter phase II trial enrolled patients with advanced NSCLC harboring uncommon <em>EGFR</em> mutations excluding exon 20 insertions. Patients received lazertinib 240 mg daily until disease progression or unacceptable toxicity. The primary end point was objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1. Secondary end points included progression-free survival (PFS), overall survival (OS), duration of response (DoR), and safety.</div></div><div><h3>Results</h3><div>Among 36 patients enrolled, the ORR was 50.0% (95% confidence interval [CI]: 34.5%–65.5%), with 18 partial responses, meeting the primary end point. Disease control rate was 88.9% (95% CI: 74.1%–96.2%). Patients with major uncommon mutations (G719X, L861Q, S768I) reported an ORR of 54.8% (17/31). Median PFS was 10.8 months (95% CI: 4.4–19.2), and median DoR was 15.1 months. G719X mutations reported the highest response (ORR 61%, median PFS 20.3 months), followed by S768I (ORR 60%) and L861Q (ORR 58%, median PFS 9.5 months). Treatment-emergent adverse events occurred in all patients, with grade 3 or higher events in 33.3%; most common were rash (47.2%), pruritus (36.1%), and muscle spasms (33.3%).</div></div><div><h3>Conclusions</h3><div>Lazertinib reported promising efficacy and a manageable safety profile in patients with NSCLC with uncommon EGFR mutations, particularly for G719X, S768I, and L861Q subtypes. These results suggest lazertinib could be an effective treatment option for this heterogeneous patient population with limited therapeutic alternatives.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 9","pages":"Pages 1279-1288"},"PeriodicalIF":20.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144002220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk-Based Lung Cancer Screening in Clinical Practice","authors":"Matthew M. Rode MD ,&nbsp;Anne-Marie G. Sykes MD ,&nbsp;Mark S. Allen MD ,&nbsp;Lori A. Ingalls MHA ,&nbsp;Hamid Rehman MD ,&nbsp;Daniel C. Deetz MD ,&nbsp;Susanne C. Degen MBA ,&nbsp;Janel N. Glantz MD ,&nbsp;Adel Zurob MBBCh ,&nbsp;Jamil Taji MD ,&nbsp;Karen L. Swanson DO ,&nbsp;Eric A. Jensen MD ,&nbsp;Laura C. Pappagallo MHA ,&nbsp;Margaret M. Johnson MD ,&nbsp;Barbara L. McComb MD ,&nbsp;Lynn M. Loosbrock MHA ,&nbsp;Andrew C. Hanson MS ,&nbsp;Ping Yang MD, PhD ,&nbsp;David E. Midthun MD ,&nbsp;Mayo Lung Screening Program","doi":"10.1016/j.jtho.2025.05.009","DOIUrl":"10.1016/j.jtho.2025.05.009","url":null,"abstract":"<div><h3>Introduction</h3><div>Current U.S. lung cancer screening guidelines use only age and smoking history; however, individual risk calculators may better stratify risk.</div></div><div><h3>Methods</h3><div>In a referred cohort design, we implemented a multisite lung cancer screening program across four states. We screened patients who qualified by either the USPSTF₂₀₁₃ criteria or a PLCO_m2012 risk of greater than or equal to 1.34%. Invasive procedures were abstracted retrospectively. We compared the incidence and prevalence of lung cancer among patients who qualified by only USPSTF₂₀₁₃ or PLCO_m2012 and along the continuum of prospective lung cancer risk using PLCO_m2012.</div></div><div><h3>Results</h3><div>Of 2471 screened patients, 114 had lung cancer. Furthermore, 84% of all patients and 91% of patients who were diagnosed with having cancer qualified by both criteria. Prevalence of lung cancers were over 7 times higher in the 10% of the cohort with the highest prospective risk than the lowest risk 10%. Incidence of cancers were higher among patients who qualified only by PLCO_m2012 (3.6 per 1000 person-years) compared with patients who qualified only by USPSTF₂₀₁₃ (0 per 1000 person-years). Of screen-detected NSCLC, 74% was stage I or II. Three (4.5%) surgical resections were performed for screen-identified nodules which proved to be benign. Overall, 106 patients (4.3%) underwent an invasive intervention due to screening.</div></div><div><h3>Conclusions</h3><div>Most patients qualified for lung cancer screening by both UPSTSF₂₀₁₃ and PLCO_m2012 criteria. Incidence cancers were higher among patients who qualified by PLCO_m2012 but not USPSTF₂₀₁₃<span> criteria. Prevalence and incidence cancer identification increased with prospective risk. Invasive procedures and resections for benign disease were relatively low.</span></div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 9","pages":"Pages 1257-1267"},"PeriodicalIF":20.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study","authors":"Roy S. Herbst MD, PhD ,&nbsp;Byoung Chul Cho MD, PhD ,&nbsp;Caicun Zhou MD ,&nbsp;Mauricio Burotto MD ,&nbsp;Manuel Cobo Dols MD ,&nbsp;Mehmet A.N. Sendur MD ,&nbsp;Vladimir Moiseyenko MD ,&nbsp;Ignacio Casarini MD ,&nbsp;Makoto Nishio MD, PhD ,&nbsp;Rina Hui M.B.B.S., PhD ,&nbsp;Elvire Pons-Tostivint MD ,&nbsp;Julia Dudnik MD ,&nbsp;Samreen Ahmed MD ,&nbsp;Chinyere E. Okpara PhD ,&nbsp;Corina Dutcus MD ,&nbsp;Lina Yin PhD ,&nbsp;Yiwen Luo PhD ,&nbsp;Diana Chirovsky PhD ,&nbsp;Niyati Bhagwati MD ,&nbsp;Delvys Rodriguez Abreu MD, PhD","doi":"10.1016/j.jtho.2025.05.016","DOIUrl":"10.1016/j.jtho.2025.05.016","url":null,"abstract":"<div><h3>Introduction</h3><div>We present the LEAP-006 (NCT03829319) phase 3 study evaluating the addition of lenvatinib to first-line pembrolizumab plus chemotherapy in metastatic nonsquamous NSCLC.</div></div><div><h3>Methods</h3><div>Adults with previously untreated stage IV nonsquamous NSCLC without targetable genetic alterations were randomized 1:1 to lenvatinib 8 mg/d or placebo once daily plus pembrolizumab 200 mg every 3 weeks with pemetrexed and carboplatin or cisplatin for 4 cycles, followed by pembrolizumab (≤35 total cycles) and pemetrexed until disease progression or intolerable toxicity. Primary end points were progression-free survival and overall survival (OS). Part 1 was an open-label safety run-in of lenvatinib plus pembrolizumab and chemotherapy; part 2 was the randomized, double-blind study.</div></div><div><h3>Results</h3><div>Participants (n = 748) were randomized to the lenvatinib (n = 375) or placebo (n = 373) arms. Median follow-up at final analysis (August 11, 2023) for OS was 36.8 months. Median (95% confidence interval [CI]) progression-free survival was 12.1 (10.4–14.1) versus 9.5 (8.3–10.7) months in the lenvatinib and placebo arms, respectively (hazard ratio, 0.88 [95% CI, 0.74–1.05]; 1-sided <em>p</em> = 0.07976). Median (95% CI) OS was 21.8 (18.6–24.0) versus 22.1 (19.7–24.2) months (hazard ratio, 1.05 [95% CI, 0.88–1.26]; 1-sided <em>p</em> = 0.70818). Grade 3 or higher treatment-related adverse events occurred in 69.7% and 55.6% of participants, respectively (grade 5, 5.6% versus 2.7%).</div></div><div><h3>Conclusions</h3><div>Adding lenvatinib to first-line pembrolizumab plus chemotherapy did not improve efficacy versus pembrolizumab plus chemotherapy in stage IV nonsquamous NSCLC without targetable genetic alterations. There were no new safety signals. Pembrolizumab plus chemotherapy remains a standard of care for this population.</div></div><div><h3>Trial registration</h3><div><span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> (<span><span>https://clinicaltrials.gov/</span><svg><path></path></svg></span>), NCT03829319</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 9","pages":"Pages 1302-1314"},"PeriodicalIF":20.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144150863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing First-Line Treatment in BRAF V600-Mut NSCLC—The Jury Is Still Out","authors":"Alona Zer MD ,&nbsp;Jair Bar MD, PhD","doi":"10.1016/j.jtho.2025.07.005","DOIUrl":"10.1016/j.jtho.2025.07.005","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 9","pages":"Pages 1169-1171"},"PeriodicalIF":20.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144988552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to “Neoadjuvant or Perioperative Chemoimmunotherapy Treatment in Patients With Resectable NSCLC: Still an Open Question” by Dafni et al.","authors":"Daniele Marinelli MD,&nbsp;Giuseppe Viscardi MD,&nbsp;Roberto Ferrara MD,&nbsp;Filippo Tommaso Gallina MD","doi":"10.1016/j.jtho.2025.06.029","DOIUrl":"10.1016/j.jtho.2025.06.029","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 9","pages":"Pages 1342-1343"},"PeriodicalIF":20.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144989669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Board of Directors","authors":"","doi":"10.1016/S1556-0864(25)00947-5","DOIUrl":"10.1016/S1556-0864(25)00947-5","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 9","pages":"Page A3"},"PeriodicalIF":20.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144989739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}